Utah

Written By Cannabis Driven Management
View Data

1. Legal and regulatory landscape

Utah only allows a medical program — adult-use remains off the table for now. Wikipedia+2Utah Department of Agriculture+2
The key law was passed by ballot measure in November 2018 (Proposition 2) enabling medical access to non-smoked forms (oils, edibles, topicals, vapes) for qualifying conditions. Wikipedia+2Utah Department of Agriculture+2
Because of the strictly regulated nature — fewer licenses, tighter rules — the structure is narrower than many adult-use states.

2. Market size & growth

The market is growing steadily. For example:

  • Annual sales: from roughly $22 million in 2020 to about $143.5 million in 2023. Utah Cannabis Information Portal

  • Per a business-analysis piece: monthly purchases have passed $15 million, with cumulative sales nearing ~$600 million since program launch. Baked In

What that tells you: there’s interest and demand, but the scale is modest compared with full adult-use markets.

3. Pricing, supply and demand dynamics

A few telling metrics:

  • Patients in Utah report spending on average about $109/month on plant-based products (all sources) with a median of ~$75.50. Utah Department of Agriculture

  • Willingness to pay (max) for a gram from a medical pharmacy averaged ~$12.15 in Utah, versus the U.S. national average of ~$9.81. Utah Department of Agriculture

  • A recent price review: flower tends to go for $12-15 per gram, with full ounces around $300-350 depending on strain; concentrates/vapes are even higher (vapes: half-gram carts $50-70; concentrates $50-80/gram). Get Med Card

What’s driving that? Two big things: limited supply and regulatory constraints. For example, Utah ranks quite low among similar states for ratio of retail locations per population. Utah
Because access is constrained, the regulated market must bear a higher cost structure. Also, competition from unlicensed or out-of-state sources puts pressure on the regulated side. Utah Department of Agriculture+1

4. Patient access & market capture

Some key notes on access and how much of demand is coming through the regulated system:

  • In a report, only ~58% of patients said there was “plenty” of supply of the products they wanted; about 42% said supply was limited or very little. Utah Department of Agriculture

  • In terms of demand capture: the regulated market captured ~40.1% of demand for flower, ~42% for vapes among the patient sample. Utah Department of Agriculture

  • Delivery/service gaps: rural regions especially lag in access (e.g., southeast Utah had the longest average distance to a pharmacy). Utah

So while the regulated market is functioning and growing, there’s still a sizeable portion of demand going un-met or being met through channels outside the regulated system. That’s a signal for opportunity (and risk).

5. Key product trends & consumer behavior

  • Vapes and cartridges appear to be leading growth in Utah. According to recent commentary, spend on vapes recently outpaced flower ($6.9 m vs $4.8 m) in one month. Baked In

  • Chronic pain remains the dominant qualifying condition for access, followed by things like PTSD, nausea. Baked In+1

  • Because prices are relatively high, patients are price-sensitive and value is a major factor. The willingness to pay above average signals that consumers are acknowledging the regulated premium — but that also limits growth if cheaper options exist outside the system.

6. Competitive and external pressures

  • Utah borders states with adult-use markets (e.g., Colorado, Nevada) which means cross-border dynamics matter: cheaper supply, tourism, diversion risks. Utah Department of Agriculture+1

  • The regulatory ceiling (medical only) means Utah’s market is inherently capped compared to states with full adult-use. Growth will largely come through deeper penetration of the medical program, product innovation, better access, and perhaps price adjustments.

  • The higher price points mean regulated providers must operate with thinner consumer numbers to reach viable volumes — which increases risk for businesses.

7. Outlook & potential areas to watch

Given your role as an analyst, here are some specific inflection points:

  • Access & network expansion: More pharmacies, better delivery, rural access improvements could capture more latent demand.

  • Product innovation and format diversification: As vapes rise, other formats (edibles, tinctures) may gain share if regulation allows.

  • Price compression potential: If supply ramps up (more cultivators/licensing) or competition increases, prices may fall, thereby growing volume.

  • Policy change / adult-use discussion: Though adult-use is not yet legalized, any shift toward broader use would dramatically change growth trajectory. As of now, resistance remains. Baked In

  • Data on illicit/out-of-state sourcing: Since a portion of demand is outside the regulated system, tracking that leakage is important — private surveys suggest Utah patients are sourcing outside the system to some degree. Utah Department of Agriculture

Key Program Metrics & Market Size

  • According to the state’s data platform, regulated sales in Utah rose from ≈ US$22.15 million in 2020 to ≈ US$143.54 million in 2023. Utah Cannabis Information Portal

  • In a media report, the program in 2024 is estimated at ≈ US$157 million, up ~14 % over 2023. Axios+1

  • Patient cardholder numbers: As of September 30, 2024, there were 89,505 active medical-plant-based cardholders in Utah. Utah Center for Medical Cannabis

  • Qualifying medical providers: As of September 30, 2024 there were 958 registered qualified medical providers (QMPs). Utah Center for Medical Cannabis

  • Program captured access metrics: A 2023 market-analysis survey found that 58 % of patients reported there was “plenty of supply” of the products they wanted, 41 % said limited/very limited supply. Utah Department of Agriculture+1

  • Illicit-market/regulated-market leakage: The same survey estimated that 59 % of cannabis product acquisitions by patients were from illicit (unregulated) sources rather than pharmacies. Utah Department of Agriculture+1

Licensing & Regulatory Structure

  • Pharmacy licenses: Utah has a cap of 15 medical-plant-based pharmacies under current statute. Utah+2Utah+2

  • Cultivation facility cap: State statute caps cultivation facilities at 8 licenses unless certain threshold conditions are met (e.g., existing licensees reach size limits, demand justified). Utah

  • Processing facilities: No statutory cap on the number of processing licenses. Utah+1

  • As of a license-count snapshot: 15 pharmacies, 8 cultivators, “15 licensed Tier 1 processors and 1 licensed Tier 2” (as of mid-2025) in one industry-overview. Cannabusiness Plans+1

  • Courier & home-delivery: Licensed pharmacies may offer home delivery via courier. Utah Center for Medical Cannabis

Product / Format & Demand Insights

  • Format trends: One secondary source reports that vape cartridges/pens have become the preferred format, overtaking flower. For example in March 2025 vape cartridges revenues were reported at ~US$7.0 m vs flower ~US$4.8 m in that month. B92.1

  • Pricing/discounting: A memorandum covering July 2024–June 2025 provides region-segmented data on average prices and discounting in pharmacies. Utah

  • Demand/price willingness: The demand-study report notes high willingness-to-pay relative to national averages (which drives pricing structure). Utah Department of Agriculture+1

Access & Supply Chain Observations

  • The regulated program’s patient capture is still incomplete: e.g., 59 % sourcing via illicit/unregulated. That suggests there remains a sizeable “shadow” supply dynamic. Utah Department of Agriculture+1

  • Geographic access: The program review noted that patients in more rural regions report access challenges (distance/travel). Utah Department of Agriculture

  • The license caps imply constrained supply infrastructure (especially 8 cultivation licensees) which may contribute to higher prices and limited variety.

  • The processing side has no cap—this suggests flexibility in manufacturing/processing could become a lever for increased product variety and throughput.

Implications for Product/Vendor Data & Brand Tracking

Given your role, here are actionable angles:

  1. Vendor/license mapping: With 8 cultivators + 15 pharmacies + variable number of processors, building a relational database (vendor→license type→location→product lines) is feasible.

  2. SKU tracking by format: Since vape/pen formats are gaining share, tracking SKU counts, launch dates, flavor/terpene profiles, cartridge sizes would be valuable.

  3. Pricing/discount data: Use the July 2024-June 2025 price-discount memorandum as baseline; monitor any deviations region-by-region for competitive strategy.

  4. Capture of illicit leakage: Since ~40 % of demand is outside the regulated system (for some formats/regions), cross-referencing regulated vs. unregulated product flows, patient behavior, brand leakage is important.

  5. Growth levers: With patient counts increasing (~100,000+ forecast), there is growth potential in deeper penetration, additional pharmacies, product format innovation. Tracking when new licenses are issued (ex: HB 54 raising pharmacy cap) will matter.

  6. Product variety/format pipeline: Processing is less constrained; therefore monitoring entry of new processors, their output and brands they service could reveal upcoming product-format changes.

1. Cultivators

There are 8 licensed cultivation facilities in Utah. Utah Center for Medical Cannabis+2The Salt Lake Tribune+2
Here are their names and locations:

Notes / implications for your database: You can build a table with columns: cultivator name, county, number of locations (if given), notes (e.g., vertical integration). For instance, Standard Wellness and Dragonfly appear as multi-location.
Also note the statute: the cap is 8 licenses unless certain thresholds are met. Utah Center for Medical Cannabis+1

2. Processors

There are 14 Tier 1 processors and 1 Tier 2 processor currently listed (plus two “intent to license”). Utah Center for Medical Cannabis+1
Some of the processor names mentioned in commentary:

Database suggestion: Create a table with processor name, tier (1 or 2), county, associated cultivator (if vertically integrated), date licensed (if available).

3. Pharmacies / Dispensing Locations

The regulated program lists 15 medical-plant-based pharmacy licenses originally. Utah Center for Medical Cannabis+1
Here are sample locations (with address, company name) from the published list:

4.9•Cannabis store•Closed

4.6•Cannabis store•Closed

4.6•Cannabis store•Closed

4.2•Cannabis store•Closed

4.7•Cannabis store•Closed

Database suggestion: Build a table with pharmacy name, parent company (if part of chain), address, county, licensing date (if found). You may need to scrape the full list since only some addresses are shown.

4. SKU / Format Data

I did not find a publicly published source that lists SKU counts or by-format SKU breakdown per pharmacy or processor in Utah. That means you will likely need to obtain that data via purchase-records/rpt or via vendor disclosures.

What is available:

Cannabis Driven Management https://NMCDM.com
Next

Market Intelligence & You